In 1928 London bacteriologist Alexander Fleming returned from vacation and found a moldy Petri dish on his desk. Around the mold spot, staphylococci had vanished — as if an invisible boundary separated life from death. This chance observation would become penicillin twelve years later, save tens of millions of lives in World War II, and bring Fleming the Nobel Prize. But 39 years before that moment, in Robert Koch's Berlin laboratory, Japanese microbiologist Kitasato Shibasaburō achieved an equally revolutionary breakthrough: he isolated a pure culture of the tetanus bacillus and, together with Emil von Behring, created the first serum in history against infection — a weapon that laid the foundation for all modern immunotherapy. Behring received the first Nobel Prize in Medicine in 1901. Kitasato received nothing, though he was nominated. Today his name is almost unknown outside Japan, and his face appeared on the new 1,000 yen banknote only in July 2024 — 93 years after his death. This is a story about how two discoveries that changed medicine forever received radically different recognition — and why global scientific memory turned out to be selective.
January 29, 1853 in Kumamoto Prefecture, southern Japan, a boy was born who would become a bridge between European and Asian science. Kitasato Shibasaburō grew up in the Meiji Restoration era — when Japan transformed from a feudal state into an industrial power in two decades, sending its best students to study in the West. In 1885 he arrived in Berlin, at Robert Koch's laboratory — the man who had just discovered the tuberculosis bacillus and developed the pure culture method, transforming bacteriology from art into exact science.
Koch was called "the microbe hunter." His laboratory at Berlin University was a factory of discoveries: here they isolated the agents of anthrax, cholera, tuberculosis. Kitasato landed at the epicenter of a revolution — when humanity first learned to see the enemy that was killing millions. Tetanus was one of these invisible killers: any scratch, any wound could become a death sentence. Muscles seized in convulsions so violent that bones broke; jaws locked shut — hence the Latin name lockjaw. The pathogen had been known since 1884, but no one could grow it in pure culture: the bacterium existed only without oxygen, and any attempt to isolate it killed the sample.
Kitasato solved the problem in 1889 by creating an anaerobic environment — sealed tubes where oxygen was displaced by hydrogen. Clostridium tetani grew in the laboratory for the first time as an obedient culture, not a chaotic mixture. This was a technical triumph, but the real breakthrough came a year later. Together with Emil von Behring, a German physician, Kitasato discovered: if you inject an animal with weakened tetanus toxin, then take that animal's blood and transfuse it to a healthy one — the second becomes immune to infection. The blood contained something that neutralized the poison. Behring called this "antitoxin," and the method "passive immunization."
In 1890 they published a joint paper. This was a manifesto of a new era: for the first time, humanity obtained a weapon not against the microbe, but against its poison — a weapon that could be transferred from one organism to another. Serotherapy was born in this article. But within a few months, the Berlin Institute for Infectious Diseases began publishing reports where Behring appeared as the sole author of the discovery. Laboratory journals showed collaborative work, but official history was written differently.
The antitoxin against diphtheria and tetanus was not just a drug — it was proof of a fundamentally new idea: immunity can be transferred. Before 1890, medicine could only prevent diseases (Jenner's vaccination against smallpox) or relieve symptoms. Serotherapy allowed for the first time to treat an already sick person by introducing ready-made antibodies from the blood of a recovered animal. This was a revolution on the scale of antibiotics — only 50 years earlier.
Diphtheria killed children by the thousands. In late 19th century Europe and the US, up to 50 thousand children died annually from suffocation caused by diphtheria membrane in the throat. Introduction of the Behring–Kitasato serum reduced mortality from 50% to 10% in a few years. Behring became a national hero of Germany, received a noble title and contracts to manufacture serum. Kitasato returned to Japan in 1892 — formally completing his studies, effectively left without recognition.
Why did the Nobel Committee in 1901 award only Behring? Official version: the prize was given for "work on serotherapy, especially for its application against diphtheria." Kitasato was nominated but did not pass. Unofficial reasons read between the lines: early 20th century European scientific circles had difficulty recognizing the priority of Asian scientists. Racial prejudices were not theory — they were part of the scientific mainstream. Kitasato published in German, worked in a German laboratory, but remained "the Japanese from Koch's lab," not an equal partner.
Behring got the glory. Kitasato learned a lesson about how global scientific hierarchy works — and that an Asian scientist would have to prove his value anew, every time. He returned to Tokyo not empty-handed: in his baggage were knowledge, methods, connections. But most importantly — determination to build in Japan its own scientific infrastructure that would not depend on European recognition.
Two years after returning, Kitasato founded the Institute for Infectious Diseases in Tokyo — Japan's first center for microbiological research. He reproduced the Berlin model: laboratories, training, production of vaccines and sera. Japan was building modern medicine from scratch, and Kitasato was its architect. But world fame came from an unexpected place: from Hong Kong, gripped by bubonic plague.
May 1894. The British colony on the brink of catastrophe: hundreds of corpses daily, streets emptying, port closed. Plague — the "Black Death" of the Middle Ages — had returned, and no one knew how to stop it. The Japanese government sent Kitasato as an expert. Simultaneously France sent Alexandre Yersin, a student of Louis Pasteur. Two teams, two approaches, one goal: find the pathogen.
Kitasato worked in the British hospital, with access to fresh corpses and modern equipment. Yersin — in an improvised laboratory, in a bamboo hut. Kitasato isolated the bacterium first, published first. But his description contained inaccuracies: he mistakenly identified Streptococcus pneumoniae, which often accompanied plague, as the pathogen. Yersin described Yersinia pestis more accurately — and it was his name that stuck to the bacterium.
Medical historians still debate who was first. Kitasato isolated the pathogen earlier, but incorrectly identified it. Yersin did it later, but correctly. The paradox is that both teams worked in parallel, both contributed — but only one name remained in the title. This episode became a symbol of a deeper problem: scientific recognition depended not only on the result, but also on what language you published in, in which journals, in which political system.
Kitasato returned to Tokyo a hero — in Japan. In the West, his work was a footnote in Yersin's reports. The language barrier was already playing its role: after World War I, German scientific literature was displaced by English-language literature. Kitasato's publications in German and Japanese remained invisible to the new generation of researchers who read only English journals.
Kitasato understood: for Japanese science to become visible, institutions must be built. He created Kitasato Institute in 1914 — an independent research center financed by private donations. Became the first dean of Keio University's medical faculty. Headed the Japan Medical Association. His students took key positions in universities, hospitals, ministries. He was building not just a career — he was building a system that could produce scientific knowledge without looking to Europe.
In 1924 Emperor Taishō conferred on him the title of baron (danshaku) — recognition no Japanese scientist before him had received. But global recognition remained unattainable. The Russo-Japanese War of 1904–1905, World War I, the rise of Japanese militarism in the 1930s — each political conflict isolated Japanese science from the West even more. Kitasato published, taught, built institutes, but his name did not make it into Western textbooks.
He died June 13, 1931, a year before the Japanese invasion of Manchuria, which finally severed ties with Western science. His legacy remained in Japan: thousands of students, dozens of research centers, diagnostic and treatment methods that saved millions of lives. But outside Japan, he was remembered only by medical historians — and not always.
September 1928. Alexander Fleming returns to the laboratory at St. Mary's Hospital in London after a two-week vacation. On his desk — dozens of Petri dishes with bacterial cultures. One of them has molded. Around the Penicillium notatum mold spot, staphylococci have disappeared. Fleming publishes the observation in 1929 but cannot isolate the active substance in stable form. The work is forgotten for ten years — until 1940, when Howard Florey and Ernst Chain at Oxford develop a method for mass production of penicillin.
1941: first clinical trials. 1943: penicillin reaches World War II fronts. By war's end, production is measured in millions of doses per month. Mortality from wound infections drops from 18% (World War I) to 1%. Penicillin saves more lives than any weapon destroys. In 1945 Fleming, Florey, and Chain receive the Nobel Prize. Fleming becomes an icon — a symbol of accidental genius who happened to be in the right place at the right time.
Why did Fleming become a legend and Kitasato a footnote? Timing. Penicillin appeared in the midst of a world war when millions needed miracles. Language. Fleming published in English, in British journals, in the era of Anglophone hegemony. Politics. Britain and the US shaped the postwar scientific order, and their heroes became global heroes. Kitasato worked in German in an era when Germany was losing wars, and in Japanese in a country becoming an enemy of the West.
But there's a deeper reason. Penicillin was an antibiotic — it killed microbes directly, a magic bullet. This was understandable, visually effective, easy for narrative. Kitasato's serotherapy was more complex: it used the immune system, required understanding of toxins, antibodies, passive immunity. This was biochemistry, not the dramatic "mold versus bacteria." Simple stories beat complex ones in the battle for attention — even if complex stories came first.
In July 2024 the Bank of Japan issued a new 1,000 yen banknote with a portrait of Kitasato Shibasaburō. 93 years after his death, he finally received symbolic recognition in his homeland — and once again remained invisible to the rest of the world. Western media did not notice the news. Microbiology textbooks mention his name in the context of tetanus, sometimes plague, but never as Fleming's equal in influence on medicine.
This is not a question of fairness. This is a question of the architecture of global scientific memory. Who decides which discoveries become canon? Who writes textbooks, selects prize laureates, forms narratives? In the 20th century the answer was simple: Anglophone institutions of the West. Language barriers, racial prejudices, geopolitical conflicts were not random obstacles — they were built-in filters that determined whose contribution would be recognized and whose forgotten.
Kitasato and Fleming solved one problem: how to stop an infection that kills millions. Kitasato did it 39 years earlier. His method — serotherapy — saved lives long before antibiotics and remains the basis of immunotherapy today. But he worked in the wrong language, in the wrong country, at the wrong time. And when Fleming accidentally discovered mold on a Petri dish, the world already spoke English, needed a hero — and chose the one who fit the narrative.
Two breakthroughs. Two eras. One memory. Kitasato laid the foundation of immunotherapy, founded institutes, trained generations of scientists — but his name remained in the shadows. Not because his work was less important. But because global science turned out not to be as global as it would like to seem. And today, when we talk about the antibiotics revolution, it's worth remembering: the first revolution in fighting infections happened not in London, but in Berlin — and it was accomplished by a man the world preferred not to notice.